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Background: Recurrent miscarriage affects approximately 1% of all couples. There is a known relation between
hypothyroidism and recurrent miscarriage. Phosphodiesterase 8B (PDE8B) is a regulator of cyclic adenosine
monophosphate (cAMP) with important influence on human thyroid metabolism. Single nucleotide polymorphism
(SNP) rs 4704397 in the PDE8B gene has been shown to be associated with variations in serum Thyroid Stimulating
Hormone (TSH) and thyroxine (T4) levels. The aim of this study was to investigate whether there is an association
between the SNP rs 4704397 in the PDE8B gene and recurrent miscarriage.
Methods: The study was designed as a retrospective case control study. 188 cases with recurrent miscarriage were
included and compared with 391 controls who had delivered at least once and with no history of miscarriage or
assisted reproduction.
Results: No difference between cases and controls concerning age was found. Bivariate associations between
homozygous A/A (OR 1.57, 95% CI 0.98-2.52) as well as G/G carriers (OR 1.52, 95% CI 1.02-2.25) of SNP rs 4704397 in
PDE8B and recurrent miscarriage were verified (test for trend across all 3 genotypes, p = 0.059). After adjustment for
known confounders such as age, BMI and smoking the association between homozygous A/A (AOR 1.63, 95% CI
1.01 - 2.64, p = 0.045) and G/G (AOR 1.52, 95% CI 1.02 - 2.27, p = 0.039) carriers of SNP rs 4704397 in PDE8B and
recurrent miscarriage remained.
Conclusions: Our findings suggest that there is an association between homozygous A/A as well as homozygous
G/G carriers of SNP rs 4704397 in PDE8B and recurrent miscarriage.
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Recurrent miscarriage affects approximately 1% of all
couples trying to conceive and is defined as three or
more consecutive pregnancy losses before 20 weeks of
amenorrhoea [1,2]. Predisposing factors include mater-
nal age, parental chromosomal aberrations, uterine ab-
normalities, antiphospholipid syndrome, immunological
and thrombophilic disorders, and endocrine diseases
such as hypothyroidism and diabetes mellitus [1]. Unlike
sporadic spontaneous miscarriage, recurrent miscarriage* Correspondence: michaela.granfors@kbh.uu.se
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reproduction in any medium, provided the ormore often occurs despite normal fetal cytogenetic find-
ings, and in 50% of cases the underlying cause remains
unexplained [1,3-5]. Hypothyroidism is a common dis-
ease, with an estimated incidence of 0.3% to 0.5% for
overt and 3% for subclinical hypothyroidism in pregnant
women [1,6-8]. There is a known relation between
hypothyroidism and recurrent miscarriage [1].
The human phosphodiesterase type 8B (PDE8B) gene
is located at human chromosome 5q14.1 in intron 1 and
encodes a high affinity cyclic adenosine monophosphate
(cAMP) specific nucleotide phosphodiesterase [9-11].
The PDE8B gene is abundantly expressed in the thyroid
but has also been detected in human placenta and ovar-
ies [9,10,12,13]. Based on a recent genome-widel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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morphisms (SNP) in the PDE8B gene were associated
with increased serum concentrations of thyroid stimulat-
ing hormone (TSH) [14]. The strongest association with
increased TSH levels (although in the normal range) was
reported for one specific SNP in PDE8B, rs 4704397,
which is found in the promoter region of the gene
[14,15]. A recent meta-analysis confirmed the associ-
ation between SNP rs 4704397 in PDE8B and elevated
TSH levels, but also found an association with decreased
levels of free T4, although free T3 levels were normal
[16]. In addition, the association between SNP rs
4704397 in PDE8B and levels of TSH has been con-
firmed in pregnant women, although no association with
free T3 or T4 levels was found [17].
In SNP rs 4704397 of PDE8B an adenine (A) nucleo-
tide is replaced by a guanine (G). The association be-
tween the polymorphism and high levels of TSH and
low free T4 levels, indicating relative hypothyroidism, is
found in homozygous carriers of A/A [16]. Based on
previous results it has been proposed that the SNP rs
4704397 in PDE8B and in particular the presence of A
alleles might induce increased phosphodiesterase activity
in PDE8B, thereby reducing the ability of the thyroid
gland to generate free T4 when stimulated by TSH [14].
Related to this, we hypothesized that homozygous car-
riers of A/A would be at increased risk of recurrent mis-
carriage. The aim of this study was to investigate
whether there is an association between the SNP rs
4704397 in the PDE8B gene and recurrent miscarriage.
Methods
Study population
The study was designed as a case–control study. Cases
(n = 188) were recruited from the Department of Obste-
trics and Gynaecology at Uppsala University Hospital,
Karolinska University Hospital, Huddinge University
Hospital and Danderyd University Hospital, Sweden. Eli-
gible cases with a diagnosis of recurrent miscarriage,
defined as three or more verified consecutive miscar-
riages in the first or second trimester of pregnancy
(5–21 completed weeks of gestation), were identified in
the out-patient registers of the participating clinics and
invited to participate in the study. The women were
included between April 29 2009 and June 30 2010.
Women with known risk factors for recurrent miscar-
riage, such as systemic lupus erythematosus, diabetes
mellitus type 1, severe thrombophilia and major
chromosomal aberrations were not included in the
study. Furthermore, two women with hyperthyroidism
were excluded.
The control subjects (n=391) were matched for age at
first planned pregnancy and were randomly chosen from
the Uppsala University Hospital biobank of pregnantwomen. Since May 31 2007, all women aged 18 and
older attending the second trimester (16–19 weeks of
gestation) routine ultrasound scan at Uppsala University
Hospital have been approached for inclusion in this bio-
bank, and inclusion to our study was ongoing until June
30 2010. In the control group, none had a history of
miscarriage and 74.9% had at least two spontaneous
pregnancies, including the ongoing pregnancy, resulting
in a term (≥37 weeks) birth of a live infant. Beyond that,
the same inclusion and exclusion criteria were applied
for the control group as for the cases.
Both cases and controls attended a brief health exam-
ination including measurements of weight and height
and answered standardised questions on reproductive
history. Further, we reviewed the medical records to ob-
tain relevant information on pregnancy outcomes, health
problems and medication.
According to routine clinical procedures, TSH-levels
were analysed in all women when diagnosed with recur-
rent miscarriage. In the case-group, hypothyroidism was
defined as TSH above the current defined upper limit of
the reference range at the different hospitals. Pregnant
controls at high risk for thyroid disease were subjected
to selected TSH screening according to local guidelines
based on international recommendations [6]. This case-
finding procedure was applied in first or early second
trimester of pregnancy, before routine ultrasound scan
and inclusion in the study.
The study was approved by the Regional Ethics Com-
mittee of the Medical Faculty of Uppsala University Hos-
pital and the Ethical Committee of the Karolinska
Institutet, Stockholm. Informed consent was obtained
from all women included in the study.
Blood sample collection
Blood samples were collected in EDTA-containing tubes
and centrifuged at 1500 g for 10 min. Plasma and buffy
coat were separated and stored at −20°C.
SNP-analysis
Genomic DNA was extracted from blood using
QIAampW DNA Blood Maxi kits (Qiagen, Venlo, the
Netherlands). The samples were genotyped for the SNP
rs4704397 of PDE8B, using the TaqManW SNP Genotyp-
ing Assay (Applied Biosystems, Foster City, CA, USA).
Briefly, PCR reactions were performed in a 96 well plate
in a total volume of 25 μl for each reaction. Each reac-
tion consisted of 1x TaqMan Universal PCR Master Mix
(PCR buffer, ROX passive reference dye, dNTPs and
AmpliTaq Gold polymerase), 1x SNP Genotyping Assay
(sequence-specific forward and reverse primers to amp-
lify the polymorphic sequence of interest, i.e. HRG exon
5, TaqManW MGB probes labelled with VIC Wdye to de-
tect allele 1 sequence and with FAM™ to detect allele 2
Table 2a Demographic data and clinical characteristics of
the study population according to the SNP rs 4704397
genotype
A/A A/G G/G
(n = 110) (n = 266) (n = 203)
Age, years 29.9 ± 5.1 30.5 ± 6.0 29.6 ± 5.8
BMI at first antenatal visit, kg/m2 23.6 ± 4.2 24.5 ± 4.4 24.1 ± 4.3
Smokers, n (%) 16 (14.5%) 31 (11.7%) 29 (14.3%)
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were initiated for 10 min at 95°C, followed by 40 cycles
of 15s at 92°C and 1 minute at 60°C. Real time fluores-
cence detection was performed. The Sequence Detection
System (SDS) Software (Applied Biosystems) was used to
plot fluorescence (Rn) values based on the signals from
each well. The plotted fluorescence signals indicated
which alleles were present in each sample.Values are mean ± standard deviation. No significant differences between the
groups exist.Statistics
Demographic and clinical characteristics were compared
between cases and controls or genotype groups using
t-test and Chi-square tests. ANOVA was used for conti-
nous variables. Adjusted odds ratios (AOR) for recurrent
miscarriage were calculated in multivariate regression
analyses using the following variables: maternal age as
completed years at the first pregnancy or first miscar-
riage, body mass index (BMI, kg/m2) defined as BMI
recorded at inclusion (cases) or BMI at first antenatal
visit (controls), smoking during pregnancy (yes/no)
defined as smoker during ≥ 1 pregnancy ending with
miscarriage (cases) or smoker at first visit to the prenatal
centre in gestational week 10 (controls), and genotype
(A/G as reference). Only variables with possible associ-
ation with each outcome (p < 0.25) in the bivariate ana-
lyses were entered into the final model. All significance
tests were two-tailed. P-values < 0.05 were considered as
statistically significant. All statistical analyses were per-
formed using SPSS 16.0 for Windows software pack
(SPSS, Chicago, IL).Results
Background characteristics and genotyping of PDE8B
Demographic data and clinical characteristics for cases
and controls are shown in Table 1. There were no
differences between cases and controls concerning age
(p = 0.99). As expected, BMI was higher (p=0.033) and
smoking (18.7% vs. 10.7%, p =0.015) and hypothyroidism
(8.5% vs. 3.1%, p = 0.006) were more common in women
with recurrent miscarriage.Table 1 Demographic data and clinical characteristics of
the study population
Cases (n = 188) Controls (n = 391) p-value
Age, years 30.1 ± 5.8 30.1 ± 5.8 0.989
BMI, kg/m2 24.7 ± 4.8 23.9 ± 4.0 0.031
Smokers, n (%) 34 (18.1%) 42 (10.7%) 0.015
Hypothyroidism, n (%) 16 (8.5%) 12 (3.1%) 0.006
Values are mean ± standard deviation; n, numbers of women; BMI, body mass
index: BMI at inclusion (cases), BMI at first antenatal visit (controls); Smokers:
smoker during ≥1 pregnancy ending with miscarriage (cases), smoker at first
visit to the prenatal center in gestational week 10 (controls); Hypothyroidism:
elevated serum TSH-levels according to local laboratory limits.Among the 579 genotyped women, 110 (19.0%) were
homozygous carriers of A/A, 266 (45.9%) were heterozy-
gous carriers (A/G) and 203 (35.1%) were homozygous
carriers of G/G (Table 2a). Homozygous A/A and G/G
carriers, compared to heterozygous carriers, were more
common among women with recurrent miscarriage
(Table 2b). Homozygous and heterozygous carriers were
in accordance with the Hardy Weinberg equilibrium.
Genotype and risk of recurrent miscarriage
A bivariate analysis was performed including all known
confounders. Based on the finding (Table 2b) that homo-
zygous A/A and G/G carriers seemed to be more com-
mon in women with recurrent miscarriage, heterozygous
A/G carriers were chosen as reference group in the
logistic regression analyses. Bivariate associations be-
tween homozygous A/A as well as G/G carriers of SNP
rs 4704397 in PDE8B and recurrent miscarriage were
verified and a test for trend across all 3 genotypes was
performed (Table 4). After adjustment for known con-
founders such as age, BMI and smoking, the association
between homozygous A/A (AOR 1.63, 95% CI 1.01 -
2.64, p = 0.045) and G/G (AOR 1.52, 95% CI 1.02 - 2.27,
p = 0.039) carriers of SNP rs 4704397 in PDE8B and re-
current miscarriage remained.
Discussion
PDE8B is known to be abundantly expressed in the thy-
roid and is of importance for thyroid function
[9,12,13,15]. Increased levels of TSH have previously
been shown in homozygous A/A carriers of SNP rs
4704397 in PDE8B and we hypothesized that there
might be an association between A allele carriers and
recurrent miscarriage. In our study, associations betweenTable 2b Distribution of SNP rs 4704397 genotype
among controls and cases
Controls (n=391) Recurrent miscarriage (cases, n=188)
All Hypothyroidism
A/A 69 (17.6%) 41 (21.8%) 3 (18.8%)
A/G 193 (49.4%) 73 (38.8%) 4 (25.0%)
G/G 129 (33.0%) 74 (39.4%) 9 (56.2%)
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SNP rs 4704397 in PDE8B and recurrent miscarriage
were found.
It has been shown that deranged levels of TSH in
serum are related to inheritable factors in 65% of cases
[18,19]. According to a genome-wide association scan in
a Sardinian population, the specific SNP rs 4704397 in
PDE8B has a strong association with increased levels of
TSH and explains 2.3% of the variance in TSH. Each
copy of the A allele was associated with an average in-
crease of 0.13 μIU/ml in TSH serum concentrations
[14].
Limitingly, as the study population was evaluated at
clinics with different reference ranges for TSH analyses,
and serum was not stored at time of diagnosis, TSH
levels were unavailable for further analysis. Thus, we
were not able to draw conclusions about whether the
increased risk of recurrent miscarriage in homozygous
A/A carriers in our material was mediated through rela-
tively increased TSH levels. However, the prevalence of
hypothyroidism was slightly, but not enough to be statis-
tically significant, greater in homozygous A/A than in G
allele carriers.
Based on the fact that homozygous A/A and G/G car-
riers, compared to heterozygous, were more common
among women with recurrent miscarriage, we decided
to use heterozygous carriers as references. This concept
has been used before in other studies. When several dif-
ferent folate-metabolizing genes were analyzed, hetero-
zygous rather than wild-type homozygous carriers,
appeared to have higher pregnancy success rate after
IVF treatment [20,21].
Not only A/A, but also homozygous carriers of the G/
G SNP rs 4704397 in PDE8B were more common
among women with recurrent miscarriage. This finding
is novel and the mediator of the association is unknown.
The association is presumably not mediated by inad-
equate thyroid metabolism, since no association between
homozygous G/G carriers and thyroid disease has been
identified in previous studies. Consistent with this, theTable 3 Factors associated with recurrent miscarriage
Unadjusted OR
(95 % CI)
Age years 1.0 (0.97-1.03)
BMI kg/m2 0.96 (0.92 – 1.00
Smoker No 1
Yes 1.84 (1.12 - 3.00
SNP rs4704397 A/G* 1
A/A 1.57 (0.98 - 2.52
G/G 1.52 (1.02 - 2.25
1adjusted for age, smoking, BMI and genotype.
*Test for trend across genotypes in relation to recurrent miscarriage was p= 0.059.prevalence of hypothyroidism in G/G carriers did not
differ from that of A/G carriers in our study population
(Table 2a). It is very likely that another mediator is
underlying this association.
Moreover, it is noteworthy that G/G carriers were
more common among hypothyroid women with recur-
rent miscarriage, compared to both controls and all
cases (Table 2b). Thus, concerning recurrent miscar-
riage, it seems to be a disadvantageous combination to
be G/G carrier and to suffer from hypothyroidism. How-
ever, it is important to remember that the number of
women with hypothyroidism is quite small in this
material.
The importance of PDE8B in the placenta and human
ovaries is unknown, but the relevance of phoshodies-
terases (PDE) in human reproduction has been discussed
[10,13]. The mechanisms that regulate oocyte maturation
in vivo and in vitro are still not well understood but the
second messenger, cyclic adenosine mono-phosphate
(cAMP), plays a critical role in maintaining the oocytes at
meiotic arrest in the diplotene stage of the first meiotic
prophase [22]. The PDEs inactivate and degrade cAMP in
oocytes as a response to the ovulatory luteinizing hor-
mone pulse and have thus been proposed as factors of im-
portance for regulating oocyte maturation [23-25].
Furthermore, it has been shown that levels of cAMP in
the oocyte at meiotic resumption correlate with oocyte
competence and embryonic development [26,27]. Based
on the knowledge that PDE activity is relevant for levels of
cAMP in oocytes, the importance of SNP rs 4704397 in
PDE8B for regulation of oocyte maturation would be one
pathway of interest for further study.
Another limitation with our study is that cases and
controls were screened for thyroid disease in different
ways. According to routine clinical procedures, TSH-
levels in all women with recurrent miscarriage were ana-
lyzed. Pregnant controls were subjected to selected TSH
screening when considered to be at high risk for thyroid
disease, in accordance with international guidelines [6].





) 0.96 (0.92-0.96) 0.026
1
) 1.86 (1.12 – 3.09) 0.017
1
) 1.63 (1.01 - 2.64) 0.045
) 1.52 (1.02 - 2.27) 0.039
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ance when the results are evaluated.
Of course, we cannot exclude our results concerning
SNP associations to be false positive. Generally, there is
a high false positive rate in small genetic association
studies due to low prior probability [28]. However, SNP
rs 4704397 in PDE8B has been shown to be associated
with variations in serum TSH levels in several studies
[14-17], and there is a well known association between
hypothyroidism and recurrent miscarriage [1]. To our
knowledge, this is the first study examining a possible
association between SNP rs 4704397 in PDE8B and re-
current miscarriage. To confirm our findings, it would
be important to increase the sample size and replicate in
an independent cohort in a further study.Conclusions
Our findings suggest that there is an association between
homozygous A/A as well as homozygous G/G carriers of
SNP rs 4704397 in PDE8B and recurrent miscarriage.
In our study, different alleles of SNP rs 4704397 in
PED8B were associated with the same outcome, recur-
rent miscarriage, but the explanation for this association
is a subject for speculation. Genetic variability plays a
role in many different diseases and has been proposed to
be of relevance in screening for distinct syndromes with
known genetic defects, and it might also be used for pre-
diction of success related to disease treatment [29,30].
Hypothetically, this specific SNP may be used for indi-
vidual counselling and for optimising treatment to pre-
vent recurrent miscarriage, based on which allele the
woman is a carrier of.
However, larger studies with independent replication
are needed to confirm our results and their clinical
importance.
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